Vesicular Stomatitis Virus (VSV)

Powerful, Robust & Flexible

Vesicular Stomatitis Virus (VSV) is a potent, rapidly replicating virus with the ability to target, infect and kill cancer cells after intravenous delivery.  Vyriad has developed proprietary technology to rapidly engineer VSV to boost its anticancer activity and to allow noninvasive monitoring in patients. Low occurrence of VSV infections in humans means most patients will not have pre-existing antiviral antibodies, allowing delivery of VSV by intravenous infusion, thereby expanding the use of oncolytic VSV in multiple cancer indications.

Vesicular Stomatitis Virus Platform

Our proprietary VSV technology serves as a robust platform from which cancer targeted oncolytic viruses are built.  The bullet-shaped virus is highly stable genetically due to its physical structure, can accommodate additional payloads, efficiently infects and spreads rapidly in cancer cells to cause cell lysis, with release of large amounts of viral progeny and tumor antigens.  VSV infections naturally occur in domestic herd animals, such as cattle and horses and, sometimes in humans working in close contact with infected animals.  Importantly, more than 90,000 individuals have been exposed to a recombinant replication competent VSV vaccine in the international rVSV-ZEBOV vaccination trials, providing unprecedented data on human experience with this viral platform.


Voyager V-1 is our lead clinical asset based on the VSV platform.  Voyager-V1 is designed for enhanced safety, efficacy and traceability through the inclusion of the interferon beta gene, enabling the virus to replicate quickly in cancer cells without damaging healthy cells, recruit cancer-fighting immune cells to the tumor, and secrete a measurable reporter protein into the blood.  Voyager-V1 was also engineered to include an iodine transporter NIS gene that facilitates tracking of the virus’ spread to cancer cells throughout the body.